Herpes Zoster Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Tech

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Herpes Zoster pipeline constitutes 18+ key companies continuously working towards developing 20+ Herpes Zoster treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Herpes Zoster Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Herpes Zoster Market.

The Herpes Zoster Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Herpes Zoster Pipeline Report: https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Herpes Zoster treatment therapies with a considerable amount of success over the years.
• Herpes Zoster companies working in the treatment market are CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc., Changchun BCHT Biotechnology, and others, are developing therapies for the Herpes Zoster treatment
• Emerging Herpes Zoster therapies in the different phases of clinical trials are- VZV Vaccine, Herpes Zoster vaccine, mRNA-1468, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others are expected to have a significant impact on the Herpes Zoster market in the coming years.
• In September 2022, The CRV-101 subunit vaccine from Curevo Vaccine, which prevents the varicella zoster virus (shingles) from reactivating in older adults, has completed a Phase IIb trial. A high-yield production process is being used to manufacture CRV-101, a highly effective and likely well-tolerated shingles vaccine.
• In February 2022, Curevo Inc. initiated a randomized observer-blind Phase II research to assess the immunogenicity and safety of the CRV-101 vaccine versus shingrix for the prevention of herpes zoster in people 50 years of age and older. divided 1:1:1 between Shingrix, the low-antigen CRV-101 vaccination, and the high-antigen CRV-101 vaccine. The research vaccinations, Shingrix and CRV-101, will be administered intramuscularly in Months 0 and 2.
• In April 2020, Changchun BCHT Biotechnology initiated a Phase III Multicenter Randomized, Doubleblind, Placebo-controlled Trial. The primary objective was to evaluate the safety and efficacy of the vaccine against herpes zoster 30 days after vaccination.

Herpes Zoster Overview
Herpes zoster (HZ), often known as Shingles, is a neurocutaneous illness that is typically brought on by the varicella-zoster virus (VZV) reactivating from a latent infection of the cranial nerve ganglia or dorsal sensory neurons that followed a previous primary infection with VZV.

Get a Free Sample PDF Report to know more about Herpes Zoster Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Herpes Zoster Drugs Under Different Phases of Clinical Development Include:
• VZV Vaccine: CPL Biologics
• Herpes Zoster vaccine: EuBiologics
• mRNA-1468 Moderna
• GLS5100: Gene One Life Science
• Z-1018 Dynavax Technologies Corporation
• EG-HZ: EyeGene
• CRV101: Curevo Inc.
• Varicella zoster virus vaccine: Changchun BCHT Biotechnology

Herpes Zoster Route of Administration
Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Herpes Zoster Molecule Type
Herpes Zoster Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Herpes Zoster Pipeline Therapeutics Assessment
• Herpes Zoster Assessment by Product Type
• Herpes Zoster By Stage and Product Type
• Herpes Zoster Assessment by Route of Administration
• Herpes Zoster By Stage and Route of Administration
• Herpes Zoster Assessment by Molecule Type
• Herpes Zoster by Stage and Molecule Type

DelveInsight's Herpes Zoster Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Herpes Zoster product details are provided in the report. Download the Herpes Zoster pipeline report to learn more about the emerging Herpes Zoster therapies at:
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Herpes Zoster Therapeutics Market include:
Key companies developing therapies for Herpes Zoster are - Immorna Biotherapeutics, Inc., ICON plc, Zhuhai Trinomab Pharmaceutical Co., Ltd., Curevo Inc, Green Cross Corporation, ModernaTX, Inc., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and others.

Herpes Zoster Pipeline Analysis:
The Herpes Zoster pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Herpes Zoster with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Herpes Zoster Treatment.
• Herpes Zoster key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Herpes Zoster Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Herpes Zoster market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Herpes Zoster drugs and therapies-
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Herpes Zoster Pipeline Market Drivers
• Increasing awareness and high demand for shingles prevention, rising incidence of herpes zoster, increasing awareness and high demand for shingles prevention, favorable reimbursement and funding policies are some of the important factors that are fueling the Herpes Zoster Market.

Herpes Zoster Pipeline Market Barriers
• However, high cost of vaccines, lack of vaccine compliance and knowledge about Shingles prevention, logistical and storage barriers, side effects associated with the current treatment options and other factors are creating obstacles in the Herpes Zoster Market growth.

Scope of Herpes Zoster Pipeline Drug Insight
• Coverage: Global
• Key Herpes Zoster Companies: CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc., Changchun BCHT Biotechnology, and others
• Key Herpes Zoster Therapies: VZV Vaccine, Herpes Zoster vaccine, mRNA-1468, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others
• Herpes Zoster Therapeutic Assessment: Herpes Zoster current marketed and Herpes Zoster emerging therapies
• Herpes Zoster Market Dynamics: Herpes Zoster market drivers and Herpes Zoster market barriers

Request for Sample PDF Report for Herpes Zoster Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Herpes Zoster Report Introduction
2. Herpes Zoster Executive Summary
3. Herpes Zoster Overview
4. Herpes Zoster- Analytical Perspective In-depth Commercial Assessment
5. Herpes Zoster Pipeline Therapeutics
6. Herpes Zoster Late Stage Products (Phase II/III)
7. Herpes Zoster Mid Stage Products (Phase II)
8. Herpes Zoster Early Stage Products (Phase I)
9. Herpes Zoster Preclinical Stage Products
10. Herpes Zoster Therapeutics Assessment
11. Herpes Zoster Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Herpes Zoster Key Companies
14. Herpes Zoster Key Products
15. Herpes Zoster Unmet Needs
16 . Herpes Zoster Market Drivers and Barriers
17. Herpes Zoster Future Perspectives and Conclusion
18. Herpes Zoster Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Herpes Zoster Market https://www.delveinsight.com/report-store/herpes-zoster-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Herpes Zoster Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Herpes Zoster Epidemiology https://www.delveinsight.com/report-store/herpes-zoster-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Herpes Zoster Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Companion Diagnostics Market
https://www.delveinsight.com/report-store/companion-diagnostics-market
Companion Diagnostics Market By Type (Product [Assays, Kits & Reagents And Instruments], and Services), Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography is expected to grow at a noteworthy CAGR till 2028 owing to the increase in the cancer burden across the globe and the growing focus on personalized medicines.

Telemedicine Service Market
https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost.

DNA Sequencing Market
https://www.delveinsight.com/report-store/dna-sequencing-market
DNA Sequencing Market By Products & Services (Instruments, Consumbales, And Services), By Technology (Sanger Sequencing, Next-Generation Sequencing, And Long-Read Sequencing), By Application (Disease Diagnosis, Precision Medicine, And Research), By End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical Companies, And Academic Institutes), and by geography is estimated to grow at an appreciable CAGR forecast till 2028 owing to rising prevalence of genetic disorders and growing popularity of precision medicine.

Next Generation Sequencing Market
https://www.delveinsight.com/report-store/next-generation-sequencing-market
Next-Generation Sequencing Market By Product Type (Instruments, Reagents & Consumables And Services), By Sequencing Type (Whole-Genome Sequencing, Whole-Exome Sequencing, Rna Sequencing, Targeted Sequencing, De-Novo Sequencing, Others), By Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, Others), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institute), by geography, is expected to grow at a significant CAGR forecast till 2028 owing to the rising application of next-generation sequencing (NGS) technology in clinical diagnosis and advancement in NGS platforms.

Active Pharmaceutical Ingredient Market
https://www.delveinsight.com/report-store/active-pharmaceutical-ingredient-api-market
Active Pharmaceutical Ingredient (API) Market By Type (Innovative And Generic), By Manufacturer Type (Captive And Merchant), By Synthesis Type (Synthetic And Biotech), By Application (Oncology, Cardiology, Pulmonology, Neurology, Orthopedic, Opthalmology, And Others), by geography is estimated to register growth at remarkable CAGR forecast till 2027 owing to rising prevalence of various diseases such as diabetes and growing focus on drug development

Clinical Diagnostics Market
https://www.delveinsight.com/report-store/clinical-diagnostics-market
Clinical Diagnostics Market By Type (Products [Instruments, Kits & Reagents], Services), Test (Complete Blood Count (CBC), Metabolic Panel, Lipid Panel, Renal Panel, Liver Panel, Infectious Disease Testing, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography, is expected to expand at a significant CAGR till 2028 owing to the growing cases of various chronic diseases & infectious diseases across the globe and rise in the integration of technological advancements in the product portfolio.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.